Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408039 · ClinicalTrials.gov registry record
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 1,331
- Enrollment target
NCT05408039: Completed study, sponsored by AstraZeneca.
NCT05408039 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 1,331 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05408039 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 1,331 participants
- Enrollment target
Study Summary
This study aims to increase the understanding of Hyperkalemia (HK) management, treatment patterns, and the treatment decision-making process for the management of patients with HK over a period of up to 12 months. The generation of real-world evidence (RWE) to understand the treatment management decision rationale and to prospectively describe patient characteristics, treatment management patterns among patients with HK is of importance to improve adherence to guidelines and improve patient care. The primary objective: • Describe HK management decisions, their rationale and treatment expectations. The secondary objective: • Describe baseline characteristics and longitudinal clinical variables in patients with HK. The exploratory objective: • Describe patient awareness and satisfaction with their HK treatment management across the study period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,331 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2024-12-19 |
What the finished NCT05408039 record still lists
NCT05408039 is an observational study that tracks outcomes without assigning an intervention. Its 1,331 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05408039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05408039 about?
NCT05408039 is a clinical study titled "Tracking Treatment Pathways in Adult Patients With Hyperkalemia.". This study aims to increase the understanding of Hyperkalemia (HK) management, treatment patterns, and the treatment decision-making process for the management of patients with HK over a period of up to 12 months. The generation of real-world evidence (RWE) to understand the treatment management dec...
What is the current status of trial NCT05408039?
This trial is currently completed. The enrollment target is 1,331 participants. The study started on 2022-07-14. Estimated completion is 2024-12-19.
Who is sponsoring clinical trial NCT05408039?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
- NCT05536011 · 1,329 participants
WAKIX® (Pitolisant) Pregnancy Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI